Table 1.

Baseline Patient Characteristics

	All patients (N=96)	Patients with CD4 counts ≥200 at 2 months (N=58)	Patients with CD4 counts < 200 at 2 months (N=38)	P-value*
Age: median (range)	57.4 (28–85)	56.6 (28–85)	60.9 (33–78)	0.07
Age: ≥55 years (%)	61 (64%)	35 (60%)	26 (66%)	0.42
Sex: Percent male	48 (50%)	30 (52%)	18 (47%)	0.68
KPS of 80–100: # (%)	90 (94%)	53(91%)	37 (97%)	0.24
Biopsy only: # (%)	19 (20%)	9 (16%)	10 (26%)	0.19
Weeks from diagnosis to treatment: median (range)	3.9 (2–12.6)	4.2 (2–12.6)	3.7 (2.3–7.6)	0.08
Baseline CD4 count: median (range)	664 (90–2010)	933 (145–2010)	401 (90–1309)	0.0001
Baseline lymphocyte count: median (range)	1418 (331–4736)	1645 (672– 4736)	1044 (331–2790)	0.0001
Baseline steroid use: # (%)	79 (82%)	44 (76%)	35 (92%)	0.04
Histology: Glioblastoma # (%)	81 (84%)	46 (79%)	35 (92%)	0.09

^*comparing subjects with CD4 counts above and below 200 at 2 months